ST. PAUL, Minn., March 14, 2012 /PRNewswire/ -- Gamma Pharmaceuticals, Inc. (PINKSHEETS: GMPM) announced today, the receipt of repeat purchase orders for Gamma Energy GEL, both 17 gram and 80 gram pack sizes from the Company’s Houston-based distribution partner. The order represents an increased commitment from Gamma’s distributor and affirmation of the Company’s distribution strategy. Gamma’s management believes that Gamma Energy GEL will quickly take its place alongside industry leader 5 Hour Energy and the two brands will fight for market share in the $10 billion energy product market. Gamma’s management is of the opinion that the days of the energy drink have passed and Gamma’s patent pending great tasting Energy GEL will win with consumers. Today, Gamma Energy GEL is selling throughout Texas, in the Midwest and in the New York Metropolitan area. The Company plans to expand nationally in the months ahead and has recently secured a vendor number from a major national chain.
Gamma and its Houston-based distribution partner are cooperating on deployment of a dedicated sales representative, territory expansion, and new outlet opening. The Distributor currently covers over 2,000 outlets in the Southwest US and is expanding their distribution footprint. Recently, Gamma hired a senior sales executive with a long history of success with both chain and independent outlets in Texas and the Southwest. His sales history in the area has enabled him to make an immediate impact. Later this month, Gamma will participate in a major Houston area trade show to promote Gamma Energy GEL to new retail accounts.
On March 7, 2012, Gamma announced a Key Appointment its Sales and Marketing department. Today’s announcement is in keeping with the Company’s push to make expanding sales the top priority in 2012.
About Gamma Pharmaceuticals Inc
Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma’s core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice nutritional supplements featuring the call to action, “You’ve made a brilliant choice for your nutrition;" SAVVY adult nutritional supplements featuring the call to action, “Be SAVVY Stay Healthy;" and,Gamma Energy Products a high performance supplement featuring the call to action, “Get Your Gamma On.” Gamma’s customer focus is on selling products in the Lifestyle of Health & Sustainability (“LOHAS”) marketplace and in the Energy Supplement Market. A series of innovative marketing programs support Gamma’s product sales and retail partners.
At present Gamma manufactures in North America, and distributes in the United States. Gamma’s products utilize proprietary “Gel Delivery Technology®", to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, superior texture, convenience and great taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well-being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company’s stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: Gamma Pharmaceuticals Inc
Joe Cunningham, President (jcunningham@gammapharma.com)
Direct: (651) 204 2048
SOURCE Gamma Pharmaceuticals, Inc.
